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Introduction
MRI offers distinct advantages for the evaluation of  liver 
disease in children, including superior tissue contrast and 
lack of  ionizing radiation. Several contrast agents targeted 
to the hepatobiliary system are also available for MRI and 
provide valuable information for characterizing liver lesions  
and the structure of  bile ducts (1, 2). These hepatobiliary 
specific contrast agents also give functional information. 
Liver disease may alter the imaging kinetics of  these agents 
—due in part to alterations in transport through the hepa-
tocyte —which may in turn suggest complex hepatobiliary 
pathology, including liver dysfunction and cirrhosis (3, 4). 
However, one area that remains to be explored is the poten-
tial role for these contrast agents in the management of  
various familial disorders of  bile formation and cholestasis. 
In this report, we present an example of  the potential im-
aging features and challenges for evaluating this patient 
population with hepatobiliary-specific MRI contrast agents.
Case report 
A 13-year-old female with a history of  PFIC type 1 
(status post cholejejunostomy at age 8 months) presented 
with increasing jaundice and pruritis, and decreasing os-
tomy output. Her medical history was otherwise unre-
markable, and her symptoms had been previously well 
managed with ursodiol, cholestyramine, and surgical bili-
ary diversion. She was found to have elevated total and 
direct bilirubin levels in the blood and was referred for 
MRI evaluation of  the abdomen and biliary system after a 
liver Doppler ultrasound study showed no abnormality.
The MRI included routine abdominal imaging se-
quences at 3 Tesla and magnetic resonance cholangiopan-
creatography (MRCP) imaging before and after the dy-
namic intravenous injection of  gadoxetate disodium 
(EOVIST, Bayer Healthcare, Wayne, NY). The liver paren-
chyma appeared normal in contour and in T1- and T2-
weighted signal characteristics. The nongadolinium portion 
of  the MRCP depicted the cholejejunostomy with no stric-
ture or obstruction, which was later confirmed by cholan-
giography performed by the retrograde injection of  iodi-
nated contrast material into the cholejejunosomy. Postcon-
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trast imaging was performed using a dynamic fast-spoiled 
gradient echo sequence with fat saturation.
The arterial and portal venous phases of  the contrast-
enhanced MRI showed normal vascular structures. How-
ever, relatively little contrast material was initially taken up 
by the liver. Instead, more contrast material was retained in 
the blood pool and drained into the hepatic veins (Fig. 1A) 
than is typically seen in normal patients who have received 
gadoxetate disodium (Fig. 1B). At 20 minutes after admini-
stration of  gadoxetate disodium, the liver parenchyma 
showed relatively little enhancement and minimal excretion 
into the bile ducts (Fig. 1C), compared with normal hepa-
tobiliary phase imaging (Fig. 1D). This lack of  hepatobili-
ary uptake of  gadoxetate disodium suggested intrinsic liver 
dysfunction, and the patient was referred for a liver biopsy. 
However, biopsy showed evidence of  cholestasis, but nor-
mal interlobular bile ducts and no evidence of  cirrhosis or 
steatohepatitis.
Discussion
An understanding of  the molecular mechanisms of  he-
patic uptake and excretion of  gadoxetate disodium (GD), 
coupled with knowledge of  the molecular defect in PFIC 
type 1, may help explain the MR imaging findings in this 
patient. GD provides excellent visualization of  hepatobili-
ary anatomy on MRI because it is readily taken up by he-
patocytes, and approximately 50% is excreted into the bili-
ary system (2). The cellular mechanism for hepatocyte up-
take relies on the organic anion-transporting polypeptide 
(OATP) family of  carriers, and subsequent biliary excretion 
occurs through the action of  multidrug resistance protein 2 
(MRP2) (1, 3, 4). 
Patients with PFIC suffer from a disruption in bile trans-
port causing cholestasis, and this ultimately leads to liver 
failure, cirrhosis, hepatocellular carcinoma, and extrahe-
patic manifestations. Three types of  PFIC have been de-
fined; the mechanisms responsible for dysfunction in bile 
transport are less well understood in PFIC type 1. PFIC 
type 1 is caused by a mutation in the ATP8B1 gene encod-
ing the FIC1 protein, a P-type adenoside triphosphatase 
found mainly on the canalicular membrane of  hepatocytes 
and in intrahepatic cholangiocytes (which are thought to 
mediate aminophospholipid translocation in the plasma 
membrane) (5, 6). 
Although the precise mechanism for cholestasis has yet to 
be elucidated, it has been postulated that a FIC1 defect 
works indirectly to disturb the secretion of  bile acids (5). 
Some investigators report that impaired FIC1 function 
results in downregulation of  nuclear receptors, such as the 
farnesoid X receptor (FXR), and that this then causes sub-
sequent downregulation of  bile transporters such as 
OATP2 and the bile-salt export pump (BSEP) (6, 7). 
This potential effect of  FIC1 on OATP2 and BSEP may 
provide the link between the autosomal recessive mutation 
in PFIC type 1 and the MRI kinetics of  GD observed in 
our patient (Fig. 2). GD shares similar mechanisms for bile 
transport as it enters the hepatocyte through OATP1 and is 
pumped into the biliary canaliculi by MRP2 (1, 3, 4). We 
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Figure 1. Comparison of relative amounts of hepatic deliv-
ery and bile excretion of gadoxetate disodium at 1.5 min-
utes (A and B) and 20 minutes (C and D) after the intrave-
nous administration of the hepatobiliary-specific contrast 
agent in the child with PFIC type 1 (A and C) and a sepa-
rate child with normal liver function (B and D). Signal inten-
sities were measured by region-of-interest analysis at the 
aorta (arrowheads) and liver parenchyma (circles) away 
from any large vessels to calculate the liver-to-aorta ratio 
(L/R). The L/R ratio was lower in the patient with PFIC type 
1 at both 1.5 and 20 minutes (L/R = 1.0 and 1.3, respec-
tively) than the patient with normal liver function (L/R = 1.2 
and 1.6, respectively). On delayed imaging, contrast ex-
creted into the bile duct (arrow in D) in the normal patient, 
but not in the patient with PFIC type 1.
hypothesize that impaired FIC1 function may downregu-
late OATP1 and MRP2, which ultimately results in poor 
hepatocyte uptake of  GD.
In conclusion, the pattern of  hepatobiliary enhancement 
seen in our patient with PFIC type 1 may be linked to the 
molecular defect that gives rise to cholestasis in these pa-
tients. A defect in F1C1 protein may cause a decreased or 
delayed transport of  gadoxetate disodium through the he-
patocyte. Our case illustrates this attenuation of  gadoxetate 
disodium kinetics as depicted on MRI. It is possible that 
hepatobiliary-targeted contrast agents such as gadoxetate 
disodium may help characterize and lend a better under-
standing to the molecular basis of  PFIC type 1. Thus, the 
use of  this imaging agent in this patient population war-
rants further investigation.
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Figure 2: Proposed link between gadoxetate disodium 
transport in hepatocytes and the molecular defect in pa-
tients with PFIC type 1. Gadoxetate disodium (GD) and bile 
salts (BS) are taken up from the blood via the organic 
anion-transporting polypeptide (OATP) family of membrane 
proteins. GD and BS are subsequently excreted into the 
bile canaliculi via multidrug resistance proteins (MRP) and 
bile-salt export pump (BSEP) at the apical membrane. A 
defect in FIC1 protein in patients with PFIC type 1 may 
work upstream to eventually decrease the transport of GD 
and BS.
